Search Results
Your search for ,New matches 16916 pages
Showing 5351 - 5400FDA Update: Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate, Statement on Product Development to Address Virus Variants
On February 4, the U.S. Food and Drug Administration (FDA) announced the scheduling of a meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization for a COVID-19 vaccine from Janssen Biotech Inc. Additionally, Acting...
Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection
Due to concerns that patients with cancer may be at higher risk for contracting the coronavirus—and may have more severe complications if infected—during the COVID-19 pandemic, hospitals and clinical practices have changed protocols to routine cancer care to reduce patients’ exposure to the virus....
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
Germline Whole-Exome Sequencing Reveals the Potential Role of Hereditary Predisposition and Therapeutic Implications in SCLC
A study presented by Nobuyuki Takahashi, MD, of the Center for Cancer Research at the National Cancer Institute, at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore (Abstract OA11.05) demonstrated that there may be an inherited ...
Development and Performance of a Population-Based Benchmark Model for Use of Cancer Surgery in High-Income Countries
In a study reported in The Lancet Oncology, Perera et al developed a population-based benchmark model for guideline-recommended use of surgery for primary cancers in high-income countries. Actual use of surgery was often consistent with model predictions but sometimes varied markedly. Study ...
Two ADAURA Analyses Support the Use of Osimertinib in Patients With Surgically Resected NSCLC
Two presentations based on data from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival outcomes for patients with surgically resected non–small cell lung cancer (NSCLC) receiving osimertinib, while also maintaining quality of life. The data were...
Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk
In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...
New Burkitt Lymphoma International Prognostic Index
As reported by Olszewski et al in the Journal of Clinical Oncology, members of The Burkitt Lymphoma International Prognostic Index Consortium have developed an index—the Burkitt Lymphoma International Prognostic Index (BL-IPI)—that provides “robust discrimination of survival” among adult patients...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
WCLC Press Briefing Focuses on the Connection Between Lung Cancer and COVID-19
On February 27, 2020, the Journal of Thoracic Oncology published a case study that described two patients from Wuhan, China, who had recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. Eleven months later, the lung...
Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma
In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...
Emil J Freireich, MD, Dies at 93
Emil J Freireich, MD, an oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized as a founding father of modern clinical cancer research, passed away on February 1. He was 93. Dr. Freireich was a faculty member at The University of Texas MD Anderson Cancer ...
Featured Presentations at WCLC Focus on Disparities in Patients With Lung Cancer
At a press briefing held by the International Association for the Study of Lung Cancer (IASLC), researchers presented new data that revealed factors relating to race, gender, sexual orientation, and income continue to be significant barriers to those living with lung cancer. The press briefing is...
Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC
The phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in patients with advanced non–small cell lung cancer (NSCLC). In a follow-up to phase I data, the phase II cohort of the study has now shown a durable response rate of 37.1%, a disease control rate...
‘State of Tobacco Control’ 2021 Report Says Ending Tobacco Use Is Critical, Especially During the COVID-19 Pandemic
Even amid the COVID-19 pandemic, tobacco use remains a serious public health threat. In addition to tobacco-related death and disease, smoking also increases the risk of the most severe impacts of COVID-19. The American Lung Association has released its 19th annual “State of Tobacco Control”...
New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on screening in survivors’ later years. The guidelines, published today by Rachel A. Freedman, MD, MPH, and ...
CheckMate 9LA Trial: First-Line Nivolumab/Ipilimumab Plus Chemotherapy vs Chemotherapy Alone in Stage IV or Recurrent NSCLC
As reported in The Lancet Oncology by Luis Paz-Ares, MD, and colleagues, the phase III CheckMate 9LA trial has shown improved overall survival with first-line nivolumab/ipilimumab plus two cycles of chemotherapy vs four cycles of chemotherapy alone in patients with stage IV or recurrent non–small...
New Clinical Calculator May Predict Recurrence Risk After Curative Colectomy for Colon Cancer
As reported in the Journal of Clinical Oncology, Weiser et al have developed a "third-generation" clinical calculator at Memorial Sloan Kettering Cancer Center (MSK), which incorporates molecular and clinicopathologic characteristics and provides an accurate prediction of disease recurrence...
FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer
The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Expert Point of View: Marco Ruella, MD
Marco Ruella, MD, of Perelman School of Medicine and Scientific Director of the Lymphoma Program, University of Pennsylvania, commented on this study on CD58 aberrations: “This is a very important study because it describes a possible new mechanism for relapse after CAR-T19 immunotherapy in...
Estimated Global Demand for Cancer Surgery and Its Associated Workforce Over the Next 2 Decades
A modeling study of global demand for cancer surgery and estimated surgical and anesthesia workforce requirements between 2018 and 2040 showed a predicted increase, which could especially impact low-income countries. These findings were published by Perera et al in The Lancet Oncology. Study...
Small Study Finds Personalized Neoantigen Vaccines May Result in Durable Immune Response for Patients With Melanoma
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response caused by the vaccine remained robust and effective in keeping cancer cells under control, according to a new study published by Hu et al in Nature Medicine. The findings demonstrate the...
Patients in Cancer Remission Also at Higher Risk for Severe COVID-19 Illness
Patients with inactive cancer who are not currently undergoing treatment also face a significantly higher risk of severe illness from COVID-19, according to a new study published by Sun et al in JNCI Cancer Spectrum. The findings underscore the importance of COVID-19 mitigation, like social...
Study Identifies Four Unique Subtypes of Small Cell Lung Cancer
Researchers have developed the first comprehensive framework to classify small cell lung cancer (SCLC) into four unique subtypes based on gene expression and have identified potential therapeutic targets for each type. These findings were published by Gay et al in Cancer Cell. SCLC is known for...
Prevalence of and Risk Associated With Breast Cancer Predisposition Genes: U.S. Population-Based Study
In a U.S. population-based, case-control study reported in The New England Journal of Medicine, Hu et al identified the prevalence of and risk associated with germline pathogenic variants in established and candidate breast cancer predisposition genes. Study Details The study involved 32,247 women...
It All Began With a Lump in the Throat
BOOKMARK Title: Milkshakes and Morphine: A Memoir of Love and LifeAuthor: Genevieve FoxPublisher: VintagePublication date: January 2019Price: $15.95, paperback, 384 pages “It doesn’t hurt, but I know it is there and I know it shouldn’t be. Interloper. I have touched it a couple of times already,...
New NCCN Resource Offers Practical Suggestions for Cancer Survivors
The National Comprehensive Cancer Network (NCCN) has announced the publication of new, free informational resources on health and wellness for cancer survivors. These two new NCCN Guidelines for Patients® are focused on healthy living and managing late and long-term side effects, and they include...
Finding Hope With Cancer
Sometimes there just is no escaping cancer. I thought I had done everything right. I was diligent about adhering to my annual physical exams, including mammograms, and routinely performed breast self-exams to spot any early changes in my breasts. Still, in the summer of 2015, I was diagnosed with...
Sarah Cannon Names Melissa Johnson, MD, Program Director of Lung Cancer Research
Sarah Cannon recently announced that Melissa Johnson, MD, has been named Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson has served as Associate Director of Lung Cancer Research...
CDC Awards Huntsman Cancer Institute $3 Million to Improve Colorectal Cancer Screening
Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a 5-year, $3 million grant from the Centers for Disease Control and Prevention (CDC) to improve Utah’s colorectal cancer screening rates. The program will build on an ongoing partnership between HCI’s Center for Health...
A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer
The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...
Research Leader Named to Rutgers Cancer Institute to Build ‘World-Class’ Cancer Immunology and Immunotherapy Programs
Rutgers Cancer Institute of New Jersey has named Christian Hinrichs, MD, as Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence, along with Eileen White, PhD, Deputy Director and Chief Scientific Officer at Rutgers Cancer...
Indian Surgical Oncologist Offers Insights Into Delivering Equitable Cancer Care in a Resource-Challenged Country
The ASCO Post is pleased to introduce this department on Global Health-Care Equity. On an occasional basis, we will publish interviews between Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, and another oncologist or cancer care specialist spanning regions around the world. Our goal is to...
Association of Community Cancer Centers Announces New Senior Director
The Association of Community Cancer Centers (ACCC) recently appointed Kristin Ferguson, DNP, RN, OCN, as Senior Director, Cancer Care Delivery and Health Policy. Dr. Ferguson will lead the organization’s initiatives to improve cancer care delivery across rural, urban, and underresourced settings,...
Novel Anti-BCMA CAR T-Cell Therapies Show Activity in Myeloma
In the treatment of relapsed or refractory multiple myeloma, chimeric antigen receptor (CAR) T-cell therapies with unique characteristics, still targeting B-cell maturation antigen (BCMA), are looking promising. At the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition,...
Innovation Discovery Grants Awarded to Mass General Brigham for Scientific Advancements in 2020
Five Innovation Discovery Grants (IDG) have been awarded to faculty from Mass General Brigham for scientific advancements, as the highly competitive IDG program exceeds $3.5 million in grants since inception. Each of the five potential patient health and health-care delivery breakthroughs for 2020...
Long-Term Follow-up of IFM 2009 Confirms Benefit of Front-Line Transplant in Myeloma
The benefit of autologous transplantation in newly diagnosed multiple myeloma has been confirmed by follow-up of the IFM 2009 trial, reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Aurore Perrot, MD, PhD, Assistant Professor of Hematology at the Cancer...
Expert Point of View: Yuan Yuan, MD, PhD
Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, commented on the IPATunity130 trial. “Targeting the PIK3CA/AKT/mTOR cancer driver pathway is the holy grail for breast cancer in general. About 30% to 40% of breast cancers carry an alteration. Activation of this pathway ...
Ipatasertib Plus Paclitaxel Falters in Advanced Triple-Negative Breast Cancer Phase III Trial
The combination of ipatasertib plus paclitaxel failed to improve progression-free survival in PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer, according to results from cohort A of the phase III IPATunity130 trial, presented at the 2020 San...
Oral Taxanes Moving Forward in Metastatic Breast Cancer
Positive results have now been reported in phase III trials of two oral taxanes in the treatment of metastatic breast cancer. At the 2020 San Antonio Breast Cancer Symposium, treatment with tesetaxel and reduced-dose capecitabine resulted in an improvement in progression-free survival of about 3...
ASCO’s New Chief Medical Officer Plans to Tackle the Global Burden of Cancer and Disparities in Access to Care
In November, ASCO announced that Julie R. Gralow, MD, FACP, FASCO, will succeed Richard L. Schilsky, MD, FACP, FSCT, FASCO, as Chief Medical Officer (CMO) of the Society. Dr. Gralow will begin her new position on February 15, 2021. Dr. Gralow’s long relationship with ASCO dates back to 1995, when...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Burkina Faso
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Burkina Faso. The aim of this special feature is to highlight the global cancer burden for various countries of...
Gastrointestinal Oncologist Laura Goff, MD, Sees Potential in Emerging Immunotherapies and Novel Targeted Agents
Laura Goff, MD, Medical Director of the Hematology and Oncology Division at Vanderbilt-Ingram Cancer Center, Nashville, was born in Chicago but reared in Lewisville, a suburb of Dallas. “I come from a long line of nurses, which early on influenced my decision to pursue a career in medicine....
Clinician Scientist Hopes to Attract New Investigators in Gynecologic Cancer by Establishing Conquer Cancer Award
Stephen A. Cannistra, MD, FASCO, was among the first scientists to define the mechanisms by which ovarian cancer cells spread throughout the peritoneal cavity. His work further defined the role of apoptosis in mediating chemotherapy-induced killing of ovarian cancer cells, as well as the...
Continuing Education Credits for Gastrointestinal Cancers Symposium
In support of improving patient care, ASCO is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health-care...
ASCO Applauds Congress for Expanding Clinical Trial Access for Medicaid Beneficiaries
Statement By Monica M. Bertagnolli, MD, FACS, FASCO, Chair of ASCO “Congress took a giant step forward to reduce health disparities by expanding clinical trial access to more than 41.6 million Medicaid beneficiaries through passage of the bipartisan CLINICAL TREATMENT Act as part of its...
Dr. Eric P. Winer Elected ASCO President for 2022–2023 Term
ASCO has elected Eric P. Winer, MD, FASCO, a long-time member and volunteer, to serve as President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the...
Chronic Graft-vs-Host Disease: Future Directions in Treatment
Hematopoietic stem cell transplantation (HSCT) has improved survival rates for several hematologic malignancies, but as the number of transplants continues to rise, community oncologists are evaluating more posttransplant complications in the clinics. The ASCO Post spoke with two of the principals...
GenesisCare Announces New Global Chief Medical Officer and Winship Cancer Institute Names Interim Executive Director
GenesisCare has appointed its first Global Chief Medical Officer, Walter J. (Wally) Curran, Jr, MD, FACR, FASCO. This appointment follows the recent acquisition of integrated cancer care provider 21st Century Oncology, increasing access to advanced cancer care for patients in more than 290...
NCCN Shares New Recommendations for Vaccinating Patients With Cancer Against COVID-19
The National Comprehensive Cancer Network® (NCCN) has released new guidance on vaccinating people with cancer against COVID-19. The nonprofit alliance of leading cancer centers created an NCCN COVID-19 Vaccine Committee that includes hematology and oncology experts with particular expertise in...
